DEK::NUP214 acts as an XPO1-dependent transcriptional activator of essential leukemia genes.
Kaya F, Bewicke-Copley F, Miettinen JJ, Casado P, Leddy E, Deniz Ö, Lavallée VP, Philippe C, Zheng J, Grebien F, Khan N, Krizsán S, Saad J, Nolin-Lapalme A, Hébert J, Lemieux S, Audemard E, Matthews J, Grantham M, Di Bella D, Wennerberg K, Parsons A, Gribben J, Cavenagh JD, Freeman SD, Bödör C, Sauvageau G, Wang J, Llamas-Sillero P, Cazier JB, Taussig DC, Bonnet D, Cutillas PR, Heckman CA, Fitzgibbon J, Rouault-Pierre K, Rio-Machin A.
Kaya F, et al.
Leukemia. 2025 Jun;39(6):1526-1531. doi: 10.1038/s41375-025-02593-8. Epub 2025 Apr 9.
Leukemia. 2025.
PMID: 40204893
Free PMC article.
The t(6;9)(p22.3;q34.1) translocation/DEK::NUP214 fusion protein defines a distinct subgroup of younger AML patients classified as a separate disease entity by the World Health Organization. ...CUT&RUN experiments demonstrated the direct binding of DEK::NUP214 t …
The t(6;9)(p22.3;q34.1) translocation/DEK::NUP214 fusion protein defines a distinct subgroup of younger AML patients classified as a …